Efficacy and Safety of Intravenous Iron Therapy for Functional Iron Deficiency Anemia in Hemodialysis Patients: A Meta-Analysis

2014 ◽  
Vol 39 (2) ◽  
pp. 130-141 ◽  
Author(s):  
Paweena Susantitaphong ◽  
Fahad Alqahtani ◽  
Bertrand L. Jaber
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Meta Analysis ◽  
Intravenous Iron ◽  
Hemodialysis Patients ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Efficacy And Safety ◽  
Functional Iron Deficiency ◽  
Intravenous Iron Therapy

Intravenous Iron Therapy: A Summary of Treatment Options and Review of Guidelines

2008 ◽  
Vol 21 (6) ◽  
pp. 431-443 ◽  
Author(s):  
Scott B. Silverstein ◽  
Jeffrey A. Gilreath ◽  
George M. Rodgers
Keyword(s):  
Molecular Weight ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Iron Dextran ◽  
Functional Iron Deficiency ◽  
Intravenous Iron Therapy

Iron replacement for iron-deficiency anemia has historically been accomplished with the use of oral iron therapy. Although oral iron is appropriate for most iron-deficiency anemia patients, many patients do not respond to or may be intolerant of oral iron, or may experience bleeding of sufficient magnitude to require higher iron doses than that achievable with oral iron. Intravenous iron therapy is a useful option for these latter patients. Three intravenous iron products are recommended: low-molecular weight iron dextran (INFeD), ferric gluconate (Ferrlecit), and iron sucrose (Venofer). These intravenous iron products have superior safety profiles compared to high-molecular weight iron dextran. The Food and Drug Administration's approval of erythropoietic-stimulating agents to treat certain types of anemia has increased usage of intravenous iron for functional iron deficiency. This review summarizes the current status of intravenous iron products and discusses their advantages and disadvantages in treating both absolute and functional iron deficiency.

scholarly journals Oral versus intravenous iron therapy in iron deficiency anemia: An observational study

2020 ◽  
Vol 9 (7) ◽  
pp. 3619
Author(s):  
PravatK Thatoi ◽  
SamarendraN Das ◽  
Amruta Devi ◽  
BibhutiB Mohanta ◽  
Anurag Choudhury ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Observational Study ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Intravenous Iron Therapy

scholarly journals Safety and Efficacy of Intravenous Iron Therapy in Postnatal Patients with Iron Deficiency Anemia

2011 ◽  
Vol 3 (1) ◽  
pp. 25-27 ◽  
Author(s):  
Shahnaz Kouser ◽  
Shaheen Kouser ◽  
Mariam Malik ◽  
Ahmad Malik
Keyword(s):  
Iron Deficiency ◽  
Prospective Study ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Allergic Reactions ◽  
Safety And Efficacy ◽  
Moderate Anemia ◽  
Intravenous Iron Therapy

ABSTRACT Objective This prospective study was conducted to establish safety and efficacy of intravenous iron therapy in postnatal anemic patients. Results Around 217 anemic women were included in the study. Most of these patients (82.2%) were of 21 to 30 years of age having parity of 2 to 4 (53.9%). Almost 71% of patients had moderate anemia with Hb of 7 to 9 gm/dl. Around 208 patients (95.86%) required two to four injections of intravenous iron to build up Hb to optimum acceptable level. Only seven patients (3.22%) suffered from minor complications of local rash, while three (1.38%) had more severe allergic reactions but were managed successfully. Conclusion Intravenous iron is a safe and effective alternative in postnatal patients as it ensures iron therapy in low resource and noncompliant patients.

scholarly journals Efficacy and safety of intravenous iron sucrose treatment in children with iron deficiency anemia

2019 ◽  
Vol 6 (10) ◽  
pp. 278-283
Author(s):  
Elif Güler Kazancı ◽  
Muhammet Furkan Korkmaz ◽  
Betül Orhaner
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Efficacy And Safety ◽  
Oral Iron Therapy ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy

Objective:  The purpose of this study is to investigate the efficacy and safety of intravenous iron sucrose treatment in children with iron deficiency anemia who were unresponsive to or could not tolerate oral iron therapy. Material and Methods: Among patients determined to have iron deficiency anemia, and were intolerant or noncompliant with oral iron therapy, 92 patients who have received parenteral iron therapy between the ages of 6 months and 18 years have been investigated retrospectively. Age, gender, patient complaints at application,  dietary characteristics, accompanying diseases and treatment complications, and safety, tolerability, and adverse events have been assessed from the information obtained from patient files. Treatment efficiency was evaluated with hemoglobin (Hb), mean corpuscular volume (MCV) and ferritin results from the blood samples taken before treatment, at the second week of treatment and after two months. Results: Mean age of patients was 12.5 ± 4.7 (age interval 1-17 years), and 21% was male while 79% was female. 72% of our patients were adolescents. From an etiological aspect, 56% of our patients was determined to have an iron-poor diet, 29% had functional menorrhagia, and 15% had chronic gastrointestinal system pathologies. Mean Hb, MCV and ferritin levels before and after treatment were found as: 7.72 ± 1.21 g/dl and 11.44 g/dl ± 0.68 g/dl;  63.2 ± 7.12  fL and  76.6 ± 3.81  fL; 3.87 ± 2.52 nmol/L and 57.94 ± 17.19  nmol/L, respectively (p< 0.001). 94% of patients were determined to have at least 2 g/dL (mean value 3.71 [range 1.6-6.3]) increase in their Hb levels. Anaphylaxis was observed in a patient who had a history of allergy despite applying premedication. Conclusion: Parenteral iron therapy is an efficient and safe treatment among indicated patients.

Effects of Oral Vitamin C on Hepcidin Levels and Erythropoietin Requirements in Functional Iron Deficiency Anemia among Hemodialysis Patients

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Mahmoud Mohamed Zaki Ali ◽  
Maha Abd ElMoniem Behairy ◽  
Reem Mohsen El Sharabasy ◽  
Ahmed Hamed Ahmed Gharib
Keyword(s):  
Iron Deficiency ◽  
Vitamin C ◽  
Iron Deficiency Anemia ◽  
Hemodialysis Patients ◽  
Deficiency Anemia ◽  
Study Group ◽  
Oral Vitamin ◽  
Functional Iron Deficiency ◽  
Serum Hepcidin ◽  
Hs Crp

Abstract Background Hepcidin has long been postulated as a key regulatory peptide in iron homeostasis. Its reduced clearance and elevated levels in hemodialysis (HD) patients lead to functional iron deficiency (FID) and ESA resistance. Vitamin C may be used as adjuvant therapy in FID anemia, but there are limited studies investigating the direct relation between vitamin C and hepcidin levels in HD patients. We aimed to test the reducing effect of Oral vitamin C therapy on hepcidin levels among hemodialysis patients with functional iron deficiency anemia. Patients and Methods This study is an open label randomized controlled clinical trial. It was conducted in the hemodialysis units of Ain Shams University hospitals. 48 adult prevalent HD patients were included and were divided into two groups. Group 1 (study group) included 31 patients who received the conventional treatment of erythropoietin stimulating agents (ESAs) together with oral supplementation of vitamin C 500 mg every other day for 3 months in addition to IV iron therapy. Group 2 (control group) included 17 patients who received only the conventional therapy of ESAs according to their hemoglobin (Hb) levels in addition to IV iron therapy. Laboratory parameters including serum hepcidin levels, highly sensitive CRP (hs-CRP) titer, CBC, kidney function tests and iron indices were measured at the baseline of the study and after 3 months. Results Oral vitamin C therapy resulted in a statistically significant reduction in both hepcidin and hs-CRP levels in the study group after 3 months. The study group showed a significant reduction in serum iron and ferritin levels (P &lt; 0.05). A Decrease in EPO requirements and elevation of hemoglobin level were observed in the study group but were not statistically significant as a short term effect of oral vitamin C, in comparison to the control group. A highly significant correlation was observed between serum hepcidin and hs-CRP (R=0.46, P&lt;0.01). Conclusion Oral vitamin C may be a promising therapy in decreasing serum hepcidin and hs-CRP levels in prevalent hemodialysis patients with functional iron deficiency anemia.

Sign in / Sign up

Export Citation Format

Share Document